Join us for an insightful session on the significant changes at the FDA brought about by the current administration, and their effects on stakeholders. Join Steve Silverman and Kwame Ulmer for a conversation covering key areas such as the drastic reduction in FDA staff, effective communication strategies in light of staff limitations, post market considerations, and strategic responses for monitoring submissions and engaging with FDA staff. Gain valuable insights into navigating these changes to ensure premarket success, regulatory compliance, and product quality.
Don't miss this opportunity to stay informed and prepared for the evolving regulatory landscape.
